Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from the Phase II the KEYNOTE-942 trial (NCT03897881), which assessed mRNA-4157, a personalized mRNA vaccine, with pembrolizumab in patients with melanoma. The vaccine, which can carry up to 34 epitopes derived from the tumor, was assessed in the adjuvant setting and resulted in improved relapse-free survival (RFS) over pembrolizumab alone. The findings additionally build upon findings from the SWOG S1801 trial (NCT03698019), which demonstrated the superiority of adjuvant and neoadjuvant therapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
